checkAd

    DGAP-Adhoc  732  0 Kommentare Merck KGaA: Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry


    Merck KGaA / Key word(s): Offer

    22.09.2014 11:56

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Merck KGaA!
    Long
    140,61€
    Basispreis
    1,11
    Ask
    × 13,28
    Hebel
    Short
    162,73€
    Basispreis
    1,24
    Ask
    × 12,52
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Merck, a leading company for innovative and top-quality high-tech products
    in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich
    Corporation ("Sigma-Aldrich"), today have entered into a definitive
    agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion
    (EUR13.1 billion), establishing one of the leading players in the $130
    billion global life science industry.

    Merck will acquire all of the outstanding shares of Sigma-Aldrich for $140
    per share in cash. The agreed price represents a 37% premium to the latest
    closing price of $102.37 on September 19, 2014, and a 36% premium to the
    one-month average closing price. The transaction is expected to be
    immediately accretive to Merck's EPS pre and EBITDA margin. Merck expects
    to achieve annual synergies of approximately EUR260 million (approximately
    $340 million), which should be fully realized within three years after
    closing.

    Bridge financing has been secured for the all-cash transaction, and Merck
    expects the final financing structure will comprise a combination of cash
    on Merck's balance sheet, bank loans and bonds. Closing is expected
    mid-year 2015, subject to regulatory approvals, approval by a special
    meeting of the shareholders of Sigma-Aldrich and other customary closing
    conditions.


    ---------------------------------------------------------------------------

    Information and Explaination of the Issuer to this News:

    Cautionary Note Regarding Forward-Looking Statements

    This communication may include 'forward-looking statements.' Statements
    that include words such as 'anticipate,' 'expect,' 'should,' 'would,'
    'intend,' 'plan,' 'project,' 'seek,' 'believe,' 'will,' and other words of
    similar meaning in connection with future events or future operating or
    financial performance are often used to identify forward-looking
    statements. All statements in this communication, other than those relating
    to historical information or current conditions, are forward-looking
    statements. We intend these forward-looking statements to be covered by the
    safe harbor provisions for forward-looking statements in the Private
    Securities Litigation Reform Act of 1995. These forward-looking statements
    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Merck KGaA: Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck KGaA / Key word(s): Offer 22.09.2014 11:56 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer